Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""van den Eertwegh AJM"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-25 z 42
Tytuł:
POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone
Autorzy:
Holleman, MS
Santi, I
Huygens, S
Aben, KKH
Van den Bergh, ACM
Bergman, AM
van den Eertwegh, AJM
Kuppen, MCP
Lavalaye, J
Mehra, NM
van Moorselaar, RJA
Van Oort, IM
Somford, DM
Westgeest, HM
Gerritsen, WR
Uyl-De Groot, CA
Pokaż więcej
Źródło:
In Value in Health January 2022 25(1) Supplement:S266-S267
Czasopismo naukowe
Szczegóły
Tytuł:
POSC365 Health State Utilities of Advanced Melanoma Patients Treated in Clinical Practice in the Era of Novel Immuno- and Targeted Therapies
Autorzy:
Franken, M
de Groot, S
van Dongen, A
Leeneman, B
Uyl-De Groot, CA
Aarts, MJB
van den Berkmortel, FWPJ
Blank, CU
Boers-Sonderen, MJ
van den Eertwegh, AJM
de Groot, JWB
Haanen, JBAG
Hospers, GAP
Kapiteijn, E
van Not, OJ
Piersma, D
van Rijn, RS
Stevense-den Boer, MAM
Suijkerbuijk, KPM
van der Veldt, AAM
Vreugdenhil, G
Wouters, MWJM
Versteegh, M
Blommestein, HM
Pokaż więcej
Źródło:
In Value in Health January 2022 25(1) Supplement:S243-S244
Czasopismo naukowe
Szczegóły
Tytuł:
P71 The Development of a Flexible and Easy to Tailor Disease Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma by Combining Trial and Real-World Data
Autorzy:
de Groot, S
Blommestein, HM
Leeneman, B
Uyl-De, Groot CA
Haanen, JBAG
Suijkerbuijk, KPM
Aarts, M.J.B.
van den Berkmortel, FWPJ
Blank, CU
Boers-Sonderen, MJ
van den Eertwegh, AJM
de Groot, JWB
Hospers, GAP
Kapiteijn, E
de Meza, MM
Piersma, D
van Rijn, RS
Stevense-den Boer, MAM
van der Veldt, AAM
Vreugdenhil, G
Wouters, MWJM
Franken, M
van Baal, PHM
Pokaż więcej
Źródło:
In Value in Health January 2022 25(1) Supplement:S16-S16
Czasopismo naukowe
Szczegóły
Tytuł:
A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.
Autorzy:
van Not OJ; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Wind TT; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands.
Ismail RK; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.
Bhattacharya A; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands.
Jalving M; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands.
Blank CU; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Medical Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Aarts MJB; Department of Medical Oncology, GROW-School for Oncology and Reproduction, Maastricht University Medical Centre+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands.
van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre Sittard, Dr. H. van der Hoffplein 1, 6162 BG Sittard-Geleen, The Netherlands.
Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
van den Eertwegh AJM; Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam UMC, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands.
de Groot JWB; Department of Medical Oncology, Isala Oncology Center, Dokter van Heesweg 2, 8025 AB Zwolle, The Netherlands.
Haanen JB; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Bloem M; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands.
van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The Netherlands.
Stevense-den Boer M; Department of Internal Medicine, Amphia Hospital, Molengracht 21, 4818 CK Breda, The Netherlands.
van der Veldt AAM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Vreugdenhil G; Department of Internal Medicine, Maxima Medical Centre, De Run 4600, 5504 DB Eindhoven, The Netherlands.
Wouters MWJM; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Blokx WAM; Department of Pathology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Fehrmann RSN; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands.
Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 May 26; Vol. 15 (11). Date of Electronic Publication: 2023 May 26.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.
Autorzy:
De Meza MM; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333AA Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Albinusdreef, 2333ZA Leiden, The Netherlands.; Division of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Blokx WAM; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.
Bonenkamp JJ; Department of Surgery, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA Nijmegen, The Netherlands.
Blank CU; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.; Division of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands.
Aarts MJB; Department of Medical Oncology, GROW-School for Oncology and Reproduction, Maastricht University Medical Center, P. Debyelaan 25, 6229HX Maastricht, The Netherlands.
van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center Sittard, Dr. H. van der Hoffplein 1, 6162BG Sittard-Geleen, The Netherlands.
Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA Nijmegen, The Netherlands.
De Groot JWB; Isala Oncology Center, Dokter van Heesweg 2, 8025AB Zwolle, The Netherlands.
Haanen JBAG; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.; Division of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands.
Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands.
Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands.
Van Not OJ; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333AA Leiden, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.
Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, 7512KZ Enschede, The Netherlands.
Van Rijn RS; Department of Internal Medicine, Medical Center Leeuwarden, Henri Dunantweg 2, 8934AD Leeuwarden, The Netherlands.
Stevense-den Boer M; Department of Internal Medicine, Amphia Hospital, Molengracht 21, 4818CK Breda, The Netherlands.
Van der Veldt AAM; Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Center, 's-Gravendijkwal 230, 3015CE Rotterdam, The Netherlands.
Vreugdenhil G; Department of Internal Medicine, Maxima Medical Center, De Run 4600, 5504DB Eindhoven, The Netherlands.
Van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, 1081HZ Amsterdam, The Netherlands.
Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.
Wouters MWJM; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333AA Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Albinusdreef, 2333ZA Leiden, The Netherlands.; Division of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Jan 07; Vol. 15 (2). Date of Electronic Publication: 2023 Jan 07.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.
Autorzy:
Rauwerdink DJW; Department of Dermatology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2300 RC Leiden, The Netherlands.
van Doorn R; Department of Dermatology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2300 RC Leiden, The Netherlands.
van der Hage J; Department of Surgery, Leiden University Medical Center, Leiden University, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands.
Haanen JBAG; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Aarts M; Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands.
Berkmortel F; Department of Medical Oncology, Zuyderland Medical Centre Sittard, Dr. H. van der Hoffplein 1, 6162 BG Sittard-Geleen, The Netherlands.
Blank CU; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Medical Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
De Groot JWB; Isala Oncology Center, Isala, Dokter van Heesweg 2, 8025 AB Zwolle, The Netherlands.
Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
de Meza M; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands.
Van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The Netherlands.
Stevense M; Department of Internal Medicine, Amphia Hospital, Molengracht 21, 4818 CK Breda, The Netherlands.
Van der Veldt A; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Vreugdenhil G; Department of Internal Medicine, Maxima Medical Centre, De Run 4600, 5504 DB Eindhoven, The Netherlands.
Wouters MWJM; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
Suijkerbuijk K; Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
van der Kooij M; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Nov 19; Vol. 14 (22). Date of Electronic Publication: 2022 Nov 19.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands.
Autorzy:
van Breeschoten J; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands.
van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands.
de Wreede LC; Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
Hilarius DL; Department of Pharmacy, Rode Kruis Ziekenhuis, Vondellaan 13, 1942 LE Beverwijk, The Netherlands.
van Zwet EW; Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
Haanen JB; Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Blank CU; Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Aarts MJB; Department of Medical Oncology, GROW School of Oncology and Developmental Biology, Maastricht University Medical Centre+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands.
van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre Sittard, Dr. H. van der Hoffplein 1, 6162 BG Sittard-Geleen, The Netherlands.
de Groot JWB; Isala Oncology Center, Isala, Dokter van Heesweg 2, 8025 AB Zwolle, The Netherlands.
Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands.
van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The Netherlands.
Stevense-den Boer MAM; Department of Internal Medicine, Amphia Hospital, Molengracht 21, 4818 CK Breda, The Netherlands.
van der Veldt AAM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Vreugdenhil G; Department of Internal Medicine, Maxima Medical Centre, De Run 4600, 5504 DB Eindhoven, The Netherlands.
Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Wouters MWJM; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Oct 11; Vol. 13 (20). Date of Electronic Publication: 2021 Oct 11.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study.
Autorzy:
van der Kooij MK; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Dekkers OM; Department of Clinical Epidemiology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, P. Debyelaan 25, 6202 AZ Maastricht, The Netherlands.
van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center, 6130 MB Sittard-Geleen, The Netherlands.
Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB Nijmegen, The Netherlands.
de Groot JWB; Isala Oncology Center, Isala, 8000 GK Zwolle, The Netherlands.
Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Piersma D; Department of Medical Oncology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands.
van Rijn RS; Department of Medical Oncology, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The Netherlands.
Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Westgeest HM; Department of Internal Medicine, Amphia Ziekenhuis, Molengracht 21, 4818 CK Breda, The Netherlands.
van der Veldt AAM; Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3000 CA Rotterdam, The Netherlands.
Vreugdenhil G; Department of Medical Oncology, Maxima Medical Center, de Run 4600, 5500 MB Veldhoven, The Netherlands.
Wilgenhof S; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Wouters MWJM; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
van den Eertwegh AJM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1117, 1081 HZ Amsterdam, The Netherlands.
Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Sep 16; Vol. 13 (18). Date of Electronic Publication: 2021 Sep 16.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors.
Autorzy:
de Glas NA; Department of Medical Oncology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Bastiaannet E; Department of Medical Oncology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.; Department of Surgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
van den Bos F; Department of Gerontology and Geriatrics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Mooijaart SP; Department of Gerontology and Geriatrics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
van der Veldt AAM; Department of Medical Oncology and Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.
Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.
van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center, 6162 BG Sittard-Geleen, The Netherlands.
Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
van den Eertwegh AJM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands.
de Groot JB; Isala Oncology Center, 8025 AB Zwolle, The Netherlands.
Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
Hospers GAP; Department of Medical Oncology, Zuyderland Medical Center, 6162 BG Sittard-Geleen, The Netherlands.; Department of Medical Oncology, University Medical Center Groningen, 9413 GZ Groningen, The Netherlands.
Jalving H; Department of Medical Oncology, Zuyderland Medical Center, 6162 BG Sittard-Geleen, The Netherlands.; Department of Medical Oncology, University Medical Center Groningen, 9413 GZ Groningen, The Netherlands.
Piersma D; Department of Medical Oncology, Zuyderland Medical Center, 6162 BG Sittard-Geleen, The Netherlands.; Department of Medical Oncology, Medisch Spectrum Twente, 7512 KZ Enschede, The Netherlands.
van Rijn RS; Department of Medical Oncology, Medical Center Leeuwarden, 8934 AD Leeuwarden, The Netherlands.
Ten Tije AJ; Department of Medical Oncology, Amphia Ziekenhuis, 4818 CK Breda, The Netherlands.
Vreugdenhil G; Department of Medical Oncology, 5504 DB Veldhoven, The Netherlands.
Wouters MWJM; Dutch Institute for Clinical Auditing, 2333 AA Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Portielje JEA; Department of Medical Oncology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Kapiteijn EW; Department of Medical Oncology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Jun 05; Vol. 13 (11). Date of Electronic Publication: 2021 Jun 05.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Autorzy:
Mulder EEAP; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.; Department of Surgical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.
de Joode K; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.
Litière S; European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands.
Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Utrecht Cancer Centre, Utrecht, The Netherlands.
Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
de Groot JWB; Department of Medical Oncology, Isala Oncological Centre, Zwolle, The Netherlands.
van den Eertwegh AJM; Department of Medical Oncology, Amsterdam University Medical Centre - location VU, Amsterdam, The Netherlands.
Aarts MJB; Department of Medical Oncology, Maastricht University Medical Centre +, Maastricht, The Netherlands.
Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands.
van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.
Vreugdenhil G; Department of Internal Medicine, Máxima Medical Centre, Veldhoven, The Netherlands.
van den Berkmortel FWPJ; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands.
Hoop EO; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.
Franken MG; Institute for Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Ryll B; Melanoma Patient Network Europe, Uppsala, Sweden.
Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Sleijfer S; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.
Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
van der Veldt AAM; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands. .; Department of Radiology & Nuclear Medicine, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Mar 25; Vol. 21 (1), pp. 323. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Immune Checkpoint Inhibitors/*administration & dosage
Melanoma/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Skin Neoplasms/*drug therapy
Withholding Treatment/*standards
Adult ; Consensus ; Drug Administration Schedule ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/standards ; Male ; Melanoma/immunology ; Multicenter Studies as Topic ; Practice Guidelines as Topic ; Prognosis ; Programmed Cell Death 1 Receptor/immunology ; Prospective Studies ; Quality of Life ; Response Evaluation Criteria in Solid Tumors ; Skin Neoplasms/immunology ; Standard of Care/standards ; Time Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-25 z 42

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies